Scientific Working Groups Saturday June 18

EHA SCIENTIFIC WORKING GROUP

19.00-20.15 hours, Auditorium

THROMBOCYTOPENIAS
Chair: F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy)

• INTRODUCTION
  F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy)
• CLINICAL DETERMINANTS AS INDICATION FOR THE TREATMENT OF ITP PATIENTS
  M. Michel (CHU Henri Mondor, Paris, France)
• METHODOLOGY OF PROSPECTIVE COHORT STUDIES IN ITP: ICIS MODEL
  T. Kühne (University Children's Hospital Basel, Basel, Switzerland)
• CLINICAL RELEVANCE OF "MILD" ITP
  A. Provan (Bart’s & The Royal London Hospital, London, United Kingdom)
• NEW PERSPECTIVES OF TPO AGONISTS IN THE TREATMENT OF ITP
  B. Godeau (CHU Henri Mondor, Paris, France)
• ITP IN HCV POSITIVE PATIENTS: A STUDY COHORT AND PROPOSAL FOR A MULTICENTER SURVEY
  A. El-Din Saad (Suez Canal University, Ismailia, Egypt)
• CONCLUSIONS AND FUTURE PROJECTS AND PRESENTATION OF THE NEW EXECUTIVE COMMITTEE
  F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy)

EHA SCIENTIFIC WORKING GROUP

19.00-20.15 hours, Forum

MYELOPROLIFERATIVE DISORDERS
Chair: T. Barbui (Ospedali Riuniti, Bergamo, Italy)

• THE ROLE OF JAK2 V617F MUTATION IN THE DIAGNOSIS OF ERYTHROCYTOSIS
  N. Casadeval (Hôpital Hôtel Dieu, Paris, France)
• THE RELATIONSHIP BETWEEN PRV-1 AND JAK-2 MUTATION IN POLYCYTHEMIA VERA
  H.L. Pahl (University of Freiburg, Freiburg, Germany)
• A COLLABORATIVE STUDY OF MYELOPROLIFERATIVE DISORDERS
  M.F. McMullin (Queen’s University of Belfast, Belfast, United Kingdom)

EHA SCIENTIFIC WORKING GROUP

19.00-20.15 hours, Room X

MYELODYSPLASTIC SYNDROMES
Chairs: P. Fenaux (Hopital Avicenne, Paris, France)
E. Hellström-Lindberg (Karolinska Institutet, Stockholm, Sweden)

• EPIGENETIC MATHS IN THE BIOLOGICAL CONTINUUM OF MDS AND AML
  M. Lubbert (University Freiburg Medical Center, Freiburg, Germany)
• APOPTOTIC PATHWAYS ACTIVATED IN ERYTHROID CELLS IN LOW GRADE MDS
  M. Fontenay (Cochin Hospital, Paris, France)
• WT1 EXPRESSION AND PROGRESSION OF MDS: ROLE FOR THE ANALYSIS OF RESIDUAL DISEASE, AND THERAPEUTIC PERSPECTIVES
  D. Cilloni (University of Torino, Torino, Italy)
• PROGRESSION OF MDS TO AML: ANIMAL MODELS
  R. Padua (Hôpital Saint-Louis, Paris, France)
• PROGRESSION OF MDS TO AML: ANALYSIS USING MICRO ARRAY TECHNOLOGY
  A. Pellagatti (John Radcliffe Hospital, Oxford, United Kingdom)

EHA SCIENTIFIC WORKING GROUP

19.00-20.15 hours, Room Y

MULTIPLE MYELOMA
Chair: P. Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands)
H. Johnsen (Herlev University Hospital, Aalborg, Denmark)

• NEWER ASPECTS IN THE CLINICAL EVALUATION OF MULTIPLE MYELOMA
  H. Ludwig (Wilhelminenspital Vienna, Vienna, Austria)
• FLOW CYTOMETRY
  A. Orfoa (University of Salamanca, Salamanca, Spain)
• FLOW CYTOMETRY
  A. Rawstron (Academic Unit of Haematology and Oncology, University of Leeds, Leeds, United Kingdom)
• ROLE OF FISH IN THE PROGNOSTIC EVALUATION OF MULTIPLE MYELOMA
  H. Avet-Loiseau (CHU-Nantes, Nantes, France)
• CYCLINS
  H. Goldschmidt (University of Heidelberg, Heidelberg, Germany)
• GENE EXPRESSION PROFILING
  P. Sonneveld (Erasmus Medical Center, Rotterdam, the Netherlands)
• MAPPING ARRAYS
  G. Morgan (Royal Marsden Hospital, London, United Kingdom)
• ONGOING TRIALS IN EUROPE
  A. Palumbo (University of Turin, Turin, Italy)
• WRAPPING UP AND CONCLUSIONS
  M. Boccadoro (University of Turin, Turin, Italy)

EHA SCIENTIFIC WORKING GROUP

19.00-20.15 hours, Room A

CHRONIC MYELOID LEUKEMIA
Chair: J. Goldman (National Heart, Lung and Blood Institute, Bethesda, USA)

• MOLECULAR HIGHLIGHTS
  G. Saglio (CHU Henri Mondor, Torino, Italy)
• RELEVANCE OF ABC TRANSPORTERS TO DRUG RESISTANCE IN CHRONIC PHASE CML
  T. Holyoake (University of Glasgow, Glasgow, United Kingdom)
• CLINICAL DECISIONS
  M. Baccarani (University of Bologna, Bologna, Italy)
• PANEL DISCUSSION
  All speakers

EHA SCIENTIFIC WORKING GROUP

19.00-20.15 hours, Room B

HEMOPHILIA
Chair: E. Berntorp (Lund University Hospital, Malmö, Sweden)

• WELCOME AND INTRODUCTION
  E. Berntorp (Lund University Hospital, Malmö, Sweden)
• THE HARMONIZATION OF HEMOPHILIA CARE ACROSS EUROPE
  J. Astermark (Lund University Hospital, Malmö, Sweden)
• TO SET UP A EUROPEAN SAFETY SURVEILLANCE SYSTEM
  P.M. Mannucci (A. Bianchi Bonomi Center, Milan, Italy)
• EUROPEAN PAEDIATRIC NETWORK FOR HEMOPHILIA MANAGEMENT (PEDNET)
  R. Ljung (Lund University Hospital, Malmö, Sweden)
• TRAINING FOR THE NEXT GENERATION OF HEMOPHILIA AND THROMBOSIS SPECIALISTS
  C. Ludlam (Royal Infirmary, Edinburgh, United Kingdom)
• EUROPEAN REGISTRY ON ACQUIRED HEMOPHILIA
  F. Baudo (Ospedale Niguarda Ca Granda, Milan, Italy)
• DISCUSSION: FUTURE ACTIVITIES WITHIN THE FRAME OF EHA
  E. Berntorp (Lund University Hospital, Malmö, Sweden)

EHA SCIENTIFIC WORKING GROUP

19.00-20.15 hours, Room L

GRANULOCYTE AND MONOCYTE DISORDERS
Chair: J. Palmblad (Karolinska Institute, Stockholm, Sweden)

• INTRODUCTION
  J. Palmblad (Karolinska Institute, Stockholm, Sweden)
• DIAGNOSIS, CLASSIFICATION, AND THERAPY OF MASTOCYTOSIS
  P. Valent (University of Vienna, Vienna, Austria)
• HEMATOLOGICAL ASPECTS OF GAUCHER DISEASE
  N. Weinreb (University Gaucher Research Foundation, USA)
• NEUTROPHIL DEFECTS IN DEVELOPMENT AND FUNCTION
  T. Kuijpers (Amsterdam Academic Medical, Amsterdam, The Netherlands)
• FREE FOR ALL: WG RELATED ISSUES, FOUNDING OF A STEERING COMMITTEE
  E. Papadaki (University Hospital of Heraklion, Heraklion, Greece)

EHA SCIENTIFIC WORKING GROUP

19.00-20.15 hours, Room C

QUALITY OF LIFE AND SYMPTOMS
Chair: C.S. Cleeland (M.D. Anderson Cancer Center, Houston, USA)

• REVIEW OF STATUS OF SYMPTOM AND QUALITY OF LIFE RESEARCH IN HEMATOLOGY
  C.S. Cleeland (M.D. Anderson Cancer Center, Houston, USA)
• POTENTIAL EDUCATIONAL INITIATIVES OF WORKING PARTY
  F.G. Wisloff (Ulleval University Hospital, Oslo, Norway)
• EXPERIENCE IN PATIENT REPORTED OUTCOMES RESEARCH IN HEMATO-ONCOLOGY
  T.I. Ionova (Multinational Center of Quality of Life, St. Petersburg,
  Russia)
• SYMPTOM BURDEN AND BMT
  S.X. Wang (M.D. Anderson Cancer Center, Houston, USA)
• COLLABORATION WITH ANOTHER EHA SWG AND OTHER GROUPS
  A.A. Novik (Multinational Center of Quality of Life, Moscow, Russia)
• DISCUSSION